These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 10823952)

  • 21. Psychological and endocrine responses to psychosocial stress and dexamethasone/corticotropin-releasing hormone in healthy postmenopausal women and young controls: the impact of age and a two-week estradiol treatment.
    Kudielka BM; Schmidt-Reinwald AK; Hellhammer DH; Kirschbaum C
    Neuroendocrinology; 1999 Dec; 70(6):422-30. PubMed ID: 10657735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats.
    Keck ME; Welt T; Wigger A; Renner U; Engelmann M; Holsboer F; Landgraf R
    Eur J Neurosci; 2001 Jan; 13(2):373-80. PubMed ID: 11168542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release.
    Merali Z; Khan S; Michaud DS; Shippy SA; Anisman H
    Eur J Neurosci; 2004 Jul; 20(1):229-39. PubMed ID: 15245495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy.
    Cleare AJ; Miell J; Heap E; Sookdeo S; Young L; Malhi GS; O'Keane V
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3545-54. PubMed ID: 11502777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure to Chronic Mild Stress Differentially Alters Corticotropin-Releasing Hormone and Arginine Vasopressin mRNA Expression in the Stress-Responsive Neurocircuitry of Male and Female Rats Prenatally Exposed to Alcohol.
    Lan N; Hellemans KG; Ellis L; Weinberg J
    Alcohol Clin Exp Res; 2015 Dec; 39(12):2414-21. PubMed ID: 26578428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.
    Mello NK; Negus SS; Rice KC; Mendelson JH
    Pharmacol Biochem Behav; 2006 Dec; 85(4):744-51. PubMed ID: 17182090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.
    Zorrilla EP; Valdez GR; Nozulak J; Koob GF; Markou A
    Brain Res; 2002 Oct; 952(2):188-99. PubMed ID: 12376179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury.
    Kosari-Nasab M; Sadeghi T; Bashiri H; Shokouhi G; Salari AA
    Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):220-228. PubMed ID: 30883392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.
    Briscoe RJ; Cabrera CL; Baird TJ; Rice KC; Woods JH
    Brain Res; 2000 Oct; 881(2):204-7. PubMed ID: 11036160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.
    Webster EL; Lewis DB; Torpy DJ; Zachman EK; Rice KC; Chrousos GP
    Endocrinology; 1996 Dec; 137(12):5747-50. PubMed ID: 8940412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.
    Gabry KE; Chrousos GP; Rice KC; Mostafa RM; Sternberg E; Negrao AB; Webster EL; McCann SM; Gold PW
    Mol Psychiatry; 2002; 7(5):474-83, 433. PubMed ID: 12082565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.
    Torres-Reverón A; Rivera-Lopez LL; Flores I; Appleyard CB
    PLoS One; 2018; 13(11):e0197698. PubMed ID: 30427841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775.
    Oshima A; Flachskamm C; Reul JM; Holsboer F; Linthorst AC
    Neuropsychopharmacology; 2003 Dec; 28(12):2148-59. PubMed ID: 12915860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats.
    Skutella T; Montkowski A; Stöhr T; Probst JC; Landgraf R; Holsboer F; Jirikowski GF
    Cell Mol Neurobiol; 1994 Oct; 14(5):579-88. PubMed ID: 7621515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of antalarmin, a novel corticotropin-releasing hormone antagonist, on the dynamic function of the preterm ovine fetal hypothalamo-pituitary-adrenal axis.
    Young IR; Chan EC; Smith R; Chrousos GP; Veldhuis JD; Canny BJ
    Neuroendocrinology; 2002 Jul; 76(1):47-54. PubMed ID: 12097816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sex and early maternal abuse on adrenocorticotropin hormone and cortisol responses to the corticotropin-releasing hormone challenge during the first 3 years of life in group-living rhesus monkeys.
    Sanchez MM; McCormack K; Grand AP; Fulks R; Graff A; Maestripieri D
    Dev Psychopathol; 2010; 22(1):45-53. PubMed ID: 20102646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice.
    Wang LA; de Kloet AD; Smeltzer MD; Cahill KM; Hiller H; Bruce EB; Pioquinto DJ; Ludin JA; Katovich MJ; Raizada MK; Krause EG
    Neuropharmacology; 2018 May; 133():85-93. PubMed ID: 29360543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.
    Ising M; Zimmermann US; Künzel HE; Uhr M; Foster AC; Learned-Coughlin SM; Holsboer F; Grigoriadis DE
    Neuropsychopharmacology; 2007 Sep; 32(9):1941-9. PubMed ID: 17287823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
    Gutman DA; Owens MJ; Skelton KH; Thrivikraman KV; Nemeroff CB
    J Pharmacol Exp Ther; 2003 Feb; 304(2):874-80. PubMed ID: 12538845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats.
    Moffett MC; Goeders NE
    Psychopharmacology (Berl); 2007 Feb; 190(2):171-80. PubMed ID: 17119930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.